Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification


Trizuljak J., Sperr W. R. , Nekvindova L., Elberink H. O. , Gleixner K., Gorska A., ...Daha Fazla

ALLERGY, cilt.75, ss.1927-1938, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 75 Konu: 8
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1111/all.14248
  • Dergi Adı: ALLERGY
  • Sayfa Sayıları: ss.1927-1938

Özet

Background: In indolent systemic mastocytosis (ISM), several risk factors of disease progression have been identified. Previous studies, performed with limited patient numbers, have also shown that the clinical course in ISM is stable and comparable to that of cutaneous mastocytosis (CM). The aim of this project was to compare the prognosis of patients with ISM with that of patients with CM.